The interferon (IFN)-induced, double stranded RNA (dsRNA)-activated serine/threonine kinase, PKR, is a potent negative regulator of cell growth when overexpressed in yeast or mammalian cells. Paradoxically, while it can function as a tumor suppressor and inducer of apoptosis, it is overexpressed in a variety of human cancers. To resolve this enigma, we established cell-lines that overexpress PKR in non-transformed and in v-mos transformed CHO cells. Overexpression of PKR suppressed the proliferation of CHO cells by inducing a transient G0/G1 arrest, followed by a delayed G2/M arrest, which attenuated cell cycle progression. These eects were accompanied by early induction of p21/ WAF-1 and delayed downregulation of CDC2 and cyclin B1. Induction of proapoptotic activity of the ectopic PKR paralleled the onset of G2/M arrest in CHO cells. However, while transiently inducing p21/WAF-1, PKR did not impose G2/M arrest or apoptosis in v-mostransformed cells, nor was CDC2 or cyclin B1 downregulated in those cells. These ®ndings link the proapoptotic activity of PKR to the arrest of cell cycle at the G2/M phase. Consequently, the apoptotic activity of PKR could be counter-acted by an oncogene-like vmos that overrides the G2/M arrest induced by PKR. Oncogene (2001) 20, 8045 ± 8056.
Introduction
The double stranded RNA (dsRNA)-activated, serine/ threonine protein kinase, PKR, is a ubiquitously expressed enzyme. It was ®rst identi®ed as a component of the interferon (IFN)-inducible cellular antiviral defense system Kerr et al., 1977) . Activation of PKR by viral dsRNA replicative intermediates results in phosphorylation of the a-subunit of the eukaryotic translation initiation factor eIF-2. Phosphorylated eIF-2a sequesters the guanine nucleotide exchange factor eIF-2B, whose role is to recycle the inactive eIF-2-GDP complex into its activated eIF-2-GTP form. This complex is necessary in order to initiate a new round of translation (Farrell et al., 1977; Proud, 1995) . The net result of eIF-2a phosphorylation is inhibition of the cell protein synthesis and the consequent inhibition of virus production (Hershey, 1991; Lee and Esteban, 1994; Meurs et al., 1992; Pain, 1996) .
PKR also acts as a signaling molecule in dsRNA and cytokine-mediated signal transduction pathways (Williams, 1995) . More speci®cally, it functions in the dsRNA-dependent activation of NF-kB, which involves the phosphorylation and subsequent degradation of IkB (Kumar et al., 1994) , as well as in cellular responses to various stresses (Williams, 1999) .
PKR null cells exhibit impaired activation of NF-kB upon TNFa stimulation and fail to activate Stat1 in response to LPS, TNFa, IFNa, and Polyriboinosinates Polyribocytidylate (Poly(I . C)) stimulation (Tan and Katze, 1999) . In addition, PKR was shown to be involved in the onset of both apoptotic and cytostatic pathways. It could induce apoptosis or growth arrest by either stimulating the phosphorylation and activation of p53 (Cuddihy et al., 1999b) or by interacting with FADD, a TNFa activated apoptotic cascade . Interestingly, both the PKR protein levels and its kinase activity change at various stages of the cell cycle Yeung and Lau, 1998) . However, whereas the enzyme protein level peaks at the G2/M stage, the PKR kinase activity is maximal during G1 phase progression and at the G1/S transition point (Zamanian-Daryoush et al., 1999) .
PKR was shown to act directly as a negative regulator of cell growth in various eukaryotic cell types. Ectopic expression of wild type PKR resulted in a pro®le of slower growth in yeast . Similarly, overexpressed PKR was manifested by a decreased proliferation rate of mammalian cells (Koromilas et al., 1992) . Moreover, ectopic expression of catalytically in-active mutants of PKR in NIH3T3 cells led to their transformation and the subsequent formation of tumors when these cells were injected into nude mice (Barber et al., 1995; Koromilas et al., 1992; Meurs et al., 1993) . This was thought to result from the interference of the overexpressed mutant protein with the growth-controlling activity of the wild type endogenous PKR (Rivas et al., 1999) . Lately, PKR activity was directly connected to the reduction in cmyc expression in tumor cells (Shang et al., 1998) .
This and accumulating evidence have now implicated PKR as a potential tumor suppressor gene; however, increased levels of an active form of PKR have been observed in a broad range of human cancers, including squamous carcinoma of the head and neck (Haines et al., 1993a (Haines et al., ,b, 1998 , lung carcinomas (Haines et al., 1992) colonicadenocarcinoma (Singh et al., 1997) and breast carcinoma (Haines et al., 1996) . Thus, the regulation and activation of PKR in transformed cells is still an enigma. To further clarify this issue, we set out to study the cellular activity of PKR in nontransformed cells and in cells that were transformed with a de®ned oncogene, v-mos.
The v-mos gene of the Moloney murine sarcoma virus (Mo-MuSV) is a potent oncogene, as was demonstrated by both its ability to transform NIH3T3 cells (Blair et al., 1981; Lohka, 1989; Maller, 1990) and by its ability to induce ®brosarcomas in mice (Canaani et al., 1983) . The mos protein is a serine/threonine protein kinase (Maxwell and Arlinghaus, 1985; Paules et al., 1992; Singh et al., 1988) that plays an essential role in the maturation of oocytes, where it is required for the activation of the maturation promoting factor (MPF) (de Moor and Richter, 1997; Yoshida et al., 2000) .
MPF is active in cell cycle regulation; it consists of a protein kinase complex that includes the CDC2 and cyclin B1 proteins (Nurse, 1990) . Importantly, MPF is required for the transition through both meiosis and mitosis (Lorca, 1993) .
It has been shown that c-mos can activate the MAP kinase, and it is involved in the stabilization of MPF (Nebreda and Hunt, 1993; Posada et al., 1993) . In addition, the transformation of NIH3T3 cells with the v-mos oncogene leads to the inappropriate expression of cell cycle components such as cyclin B1 and CDC2. Interestingly, the levels of the CDC2 mRNA, CDC2 protein, and its associated kinase activity, all of which are normally down-regulated in serum-starved cells, were barely aected in serum-starved v-mos-transformed cells (Afshari et al., 1997; Rhodes et al., 1997) .
Here, we studied the eect of PKR on cell growth in the absence or the presence of an oncogene that exerts its transforming activity by directly aecting cell cycle regulation.
Results

Cytostatic effects of ectopic PKR in CHO cells
To study the cellular eects of PKR in transformed and non-transformed cells, we established an ecdysoneregulated, PKR ectopic expression system in nontransformed and in v-mos-transformed CHO cells. In this system, induction is based on the activation of a heterodimer of the receptor for the insect hormone ecdysone (VgEcR) and the retinoid X receptor (RXR) that binds a modi®ed ecdysone response element (EcRE) in the presence of the ligand ecdysone (or a synthetic analog, muristerone A). Binding of the heterodimer to EcRE in the pIND expression vector activates the transcription and production of the ectopic protein .
Cells transfected with the G-418-resistant plasmid alone (CHO:Neo) served as controls for both v-mostransformed and non-transformed cells, expressing ectopic PKR. Several independent ectopic PKRexpressing clones were isolated and their muristerone A-dependent production of PKR was determined. Most of the responding non-transformed cells (CHO : PKR) exhibited tightly regulated expression of the ectopic PKR ( Figure 1A ). Of these, at least two independent clones (6 and 14) had induced expression levels of ectopic PKR that were comparable to the IFN-induced expression levels of the endogenous PKR ( Figure 1A ). In the present study these clones were further analysed. Regulated expression of the ectopic PKR was also observed in v-mos-transformed cells (CHO:mos:PKR). However, the basal expression levels of the endogenous enzyme seemed to be relatively high, as can be observed from the PKR levels detected in the v-mos-transformed clones that were transfected with only the neo gene ( Figure 1B) .
To study the eects of overexpressed PKR on the growth pro®les of non-transformed CHO cells, we induced ectopic PKR expression in clones 6 and 14 for up to 4 days (96 h). Subsequently, the cell growth Whole cell extracts were prepared from CHO : v-mos:Neo (Neo) cells and from CHO:v-mos:PKR cells (clones 5 and 9) that were untreated (7) or treated (+) with muristerone A for 24 h. PKR levels were determined by Western blot analysis, using aPKR antibodies. The arrow on the left indicates the migration distance of PKR curves were determined and were then compared to those of non-induced CHO : PKR cells and to CHO:Neo clones. No interference with the cell proliferation could be seen in CHO:Neo clones either treated with muristerone A or left untreated, for up to 5 days (Figure 2A ). However, induction of ectopic PKR expression led to a marked reduction in the CHO cell proliferation level, which was most apparent after 96 h ( Figure 2B ).
To determine whether the delayed interference of PKR with cell proliferation results from the interference of the enzyme with cell cycle progression or the induction of apoptosis or both, we analysed the¯ow cytometry of ectopic PKR expressing and nonexpressing cells.
PKR confers G2/M arrest and induces apoptosis in overexpressing cells
CHO : PKR cells were exposed to muristerone A for 4 days (96 h) and their cell cycle pro®les were determined after each day. Although no obvious eects were observed after 24 h ( Figure 3A ,B), treatment with muristerone A for 48 h increased the proportion of cells residing at the G0/G1 phase by an average of 30% ( Figure 3C,D) . This was accompanied by a decrease of about 16% in the proportion of S phase cells ( Figure  3C ,D). However, after 72 and 96 h of muristerone A stimulation, the overall cell-cycle pro®les of the CHO : PKR cells changed. In untreated cells, we observed a gradual increase in the G0/G1 population, which most probably results from the increasing density of the actively growing cells (Figure 3 ). In treated cells however, although a substantial reduction (30%) in the S phase could still be observed, a marked increase in the G2/M fraction appeared upon extended exposure of the cells to muristerone A. This increase ranged from a 100% increase after 72 h of muristerone treatment to a 150% increase after 96 h ( Figure 3E ± H). Thus, in accordance with the CHO : PKR clone proliferation curves (Figure 2 ), the most prominent eect of PKR on the cell-cycle progression of CHO : PKR cells was observed after 72 and 96 h.
To determine whether the proapoptotic activity of PKR changes concomitantly with the varying eects of the enzyme on cell-cycle progression, the induced apoptotic activity of PKR was analysed in CHO : PKR cells, at dierent time periods of muristerone A treatment. However, while ectopic PKR exerted cytostatic eects in CHO cells, the basal apoptotic activity of the enzyme was relatively low (data not shown). We thus increased the activation states of the enzyme by exposing the cells to poly(I . C), a potent activator of PKR (Tan and Katze, 1999) . To this end, CHO : PKR cells were incubated with muristerone A for 24 ± 96 h and were then exposed to poly(I . C), for the last 18 h before each harvest point. Induction of the proapoptotic activity of PKR was followed by staining the cells with labeled annexin V and evaluating the fraction of apoptotic cells by¯ow cytometry analysis. Remarkably, the induced ectopic PKR levels were similar at all times ( Figure 4A ), and poly(I . C) led to similar biochemical activation levels of PKR in vivo, at all times analysed ( Figure 4B ± 48 h, and 24 and 72 h ± data not shown). However, a time-dependent increase in the percentage of apoptotic cells was seen when cells were induced to ectopically express PKR. The highest apoptotic activity was observed when cells were induced to express ectopic PKR for 96 h, and were then treated with poly(I . C) for the last 18 h. That combined treatment initiated apoptosis in 64% of the cells ( Figure 5F ). The observed apoptotic process was initiated by PKR since the addition of 2-aminopurine, a known inhibitor of PKR, abolished that apoptotic activity ( Figure 5G ,H. Thus, the onset of potential proapoptotic activity of PKR parallels the G2 to M interfering activity of the enzyme. Both eects were maximal after 96 h of ectopic PKR production ( Figures 5F and 3H ). This ®nding led us to check whether the G2/M arrest is linked to the onset of the potential proapoptotic activity of PKR.
PKR does not induce apoptosis in G0/G1-enriched culture
To determine whether the proapoptotic activity of PKR is linked to the G2/M arrest imposed by the enzyme, the kinase was ectopically expressed in a cell culture enriched for G0/G1 cells. CHO : PKR cells were grown to con¯uence, a state that enabled the enrichment of the G0/G1 subpopulation without further exposure of cells to stress-causing drugs or to serum deprived growth conditions (Hannigan and Williams, 1986) . The expression of ectopic PKR was then induced for 3 or 4 days and the level and kinase activity of the ectopically expressed enzyme were determined using SDS ± PAGE and Western blot analysis. Stimulation of a con¯uent CHO : PKR culture containing 60% G0/G1 cells ( Figure 6A ,B), with muristerone A for 3 days, induced ectopic PKR levels ( Figure 7A ) and PKR kinase activity ( Figure 7B ) to levels that were comparable to those obtained in an actively growing culture (Figure 4) . However, when the G0/G1-enriched cell population was stimulated with muristerone A for 3 days and was then treated with poly(I . C), no proapoptotic activity of PKR could be observed ( Figure 6C,D) . Similar results were obtained The dark grey area in the histogram represents G0/G1 cells, the black area represents S phase cells, and the light grey denotes G2/M cells. The presented pro®les were obtained in one out of ®ve independent experiments that gave similar results with con¯uent CHO:PKR cultures that were stimulated with muristerone A for 4 days (data not shown). Thus, ectopic PKR does not induce apoptosis in G0/G1-arrested culture, and its proapoptotic activity is linked rather speci®cally to the attenuation of G2/M progression.
PKR down-regulates CDC2 and cyclin B1 in CHO : PKR cells
The transition between the consecutive stages of eukaryotic cell cycle progression is a tightly controlled process. We therefore decided to explore the molecular mechanisms that underlie the interference of PKR with the G2 to M transition. Since the kinase complex CDC2/cyclin B1 plays a key role in G2 to M progression (Kishimoto, 1999) , we decided to check the eect of PKR on the constituents of that complex. CHO : PKR clones were induced to express the ectopic enzyme for up to 72 h. Whole cell protein extracts were prepared at dierent times during the induction process and the relative levels of CDC2 and cyclin B1 were determined by Western blot analysis. Although, the levels of a-actin were similar in all extracts ( Figure 8B ), the levels of CDC2 dropped signi®cantly after 48 h of muristerone A stimulation and decreased further at 72 h of induction ( Figure 8A ). A similar pro®le was obtained for cyclin B1, whose cellular level dropped signi®cantly after 48 h of muristerone A treatment ( Figure 8C ). This decline in the CDC2/cyclin B1 levels preceded the onset time of the G2/M arrest imposed by the ectopic PKR ( Figure 3 ) and may thus lead to that arrest. Interestingly, PKR did not aect the cellular levels of cyclin D1 ( Figure 8D ). It did, however, increase transiently the cellular levels of Ser 392 phosphorylated and activated p53 and of p21/WAF-1 ( Figure 8F and E, respectively) . The levels of p21/WAF-1 increased after 24 and 48 h of ectopic PKR induction but dropped to their basal level after 72 h ( Figure 8E ).
PKR induces neither G2/M arrest nor apoptosis in v-mos-transformed cells
After characterizing the cytostatic and proapoptotic activity of ectopic PKR in CHO : PKR clones, we began analysing those cellular eects in v-mostransformed CHO cells. CHO : v-mos : PKR cells were induced to ectopically express PKR up to 4 days (96 h) and their growth and apoptotic pro®les were followed. Unlike CHO : PKR cells whose proliferation level was greatly aected by extended ectopic PKR expression, no such eect was seen in the growth curves of v-mostransformed cells (Figure 9 ). Accordingly, no obvious eect of ectopic PKR on the cell cycle pro®le of v-mostransformed cells could be seen ( Figure 10A,B) . To determine whether the lack of cytostatic eects of PKR in CHO : v-mos : PKR cells re¯ect the inability of the enzyme to induce p21/WAF-1, or to down-regulate the CDC2/cyclin B1 complex in those cells, the cellular levels of p21/WAF-1 CDC2 and cyclin B1 were determined in muristerone-treated CHO : v-mos : PKR cells. Despite the fact that the ectopic PKR exhibited relatively high kinase activity after 3 days of muristerone A treatment ( Figure 11D ), transiently activated p53 (Figure 11f ) and induced p21/WAF-1 ( Figure  11C ), the enzyme had no eect on the CDC2/cyclin B1 levels ( Figure 11A,B) .
Next, we analysed the potential proapoptotic activity of ectopic PKR in CHO : v-mos : PKR cells. To this end, cells were stimulated with muristerone A and were then treated with poly(I . C) at dierent times after muristerone A induction. Although, the ectopic kinase activity of PKR could be eciently induced in these cells ( Figure 11D ), no indication of PKR proapoptotic activity could be seen even after 72 h ( Figure 10C,D) or 96 h of muristerone A treatment (data not shown). Thus, neither cytostatic nor any apoptotic activity of overexpressed PKR could be observed in v-mostransformed cells.
Discussion
PKR is a serine/threonine protein kinase that was shown to play a role in various pro-in¯ammatory and stress-activated pathways (Ito et al., 1999; Tan and Katze, 1999; Williams, 1999) . Overexpression of the native and dominant negative mutants of PKR directly demonstrated the growth regulatory and proapoptotic C)-Sepharose beads and was then subjected to an in vivo kinase assay. 32 P-labeled autophosphorylated kinase was resolved by SDS ± PAGE and was then detected by autoradiography. The arrow on the left indicates the migration distance of PKR activity of that enzyme Meurs et al., 1993) . Although, several apoptotic cascades have been shown to integrate into PKR, the molecular mechanisms that underlie the growth modulatory activity of that kinase are still elusive. The primary cellular substrate of PKR is the a subunit of the translation initiation factor eIF2 Lu et al., 1999) and this phosphorylation is essential for induction of apoptosis by PKR (Gil et al., 1999) . However, the molecular Figure 5 Proapoptotic activity of ectopic PKR in CHO : PKR cells. CHO : PKR cells that where either untreated (7PKR) or treated (+PKR) with muristerone A for up to 4 days (96 h) were treated with poly(I . C), and were then harvested every 24 h. After 96 h, some of the cells were also treated with 2-aminopurine (G and H). The cells were co-stained with propidium iodide and annexin V, and were then analysed by¯owcytometry. Apoptotic cells that bind annexin V are represented by the two right hand rectangles. The percentage of apoptotic cells is given in the two right rectangles in the insert of each pro®le. The presented pro®les were obtained in one out of ®ve independently repeated experiments that gave similar results events that link the inactivation of eIF2a to the proapoptotic activity of the enzyme is not well understood. Moreover, unexpectedly, an active form of PKR is highly and constitutively expressed in a variety of human cancers (Haines et al., 1993a (Haines et al., ,b, 1998 Kim et al., 2000; Singh et al., 1997) . One might think of several possible explanations for this enigma. First, in tumor cells the activity of the enzyme could be inhibited by a battery of cellular proteins that can render PKR inactive Li et al., 2000; Melville et al., 2000) . Recently, a splice variant of the PKR transcript, encoding a dominant negative form of the enzyme, was detected as well in various human tissues. Interestingly, expression of that form was signi®cantly high in the T-acute lymphoblastic leukemia jurkat cells (Li and Koromilas, 2001 ). Last but not least there is the possibility that activation of signal transduction pathways by certain oncogenes overrides the cytostatic activity of PKR. Indeed, one such case was reported with Ras transformed cells Faller, 1992, 1994) .
In the present study we show that ectopically overexpressed PKR exerts two major eects on cell cycle progression of non-transformed cells. PKR 
Figure 7
Induced ectopic PKR levels and kinase activity in con¯uent CHO:PKR cells. Whole cell protein extracts were prepared from con¯uent CHO:PKR cells that were either untreated (7) or treated (+) with muristerone A for 3 days. (A) PKR levels were determined by Western blot analysis. (B) The induced PKR kinase activity was determined in an in vivo kinase assay. The 32 P-labeled autophosphorylated PKR was resolved in SDS ± PAGE and was then detected by autoradiography transiently attenuates the cell cycle G1/S transition and consequently increases the fraction of cells that reside in the G0/G1 phase (Figure 3 ). This could result from the transient induction of p21/WAF-1 by PKR ( Figure  8E ), or by inhibiting c-myc expression (Shang et al., 1998) . PKR was found to act as an activator of p53 both in vivo and in vivo (Cuddihy et al., 1999b, and Figure 8F ). Thus, PKR induces p21/WAF-1 most probably by a p53-dependent pathway that results in an impaired G1/S transition (Cuddihy et al., 1999a) . A similar eect of PKR on p21/WAF-1 was seen in myogenic cells where overexpression of PKR led to p21/WAF-1 induction, dephosphorylation of pRb, and consequently G0/G1 arrest and terminal dierentiation (Kronfeld-Kinar et al., 1999; Salzberg et al., 2000) . However, this eect of overexpressed PKR in CHO cells is transient and extended overexpression of PKR seems to concomitantly induce p53 or p21/WAF-1 down-regulating factors. At late stages of PKR overexpression, the G0/G1 arrest is reversed and a G2/M arrest takes over (Figure 3 ). It should be noted however that in clones expressing relatively low levels of ectopic PKR, the G0/G1 arrest prevailed and was not followed by a signi®cant G2/M arrest (data not shown). Thus G2/M arrest is linked to high expression level of PKR. This results most probably from downregulation of the CDC2 and cyclin B1 levels by PKR, which decreased the cellular levels of both CDC2 and cyclin B1 by more than 10-fold (Figure 8) .
The down-regulation of the CDC2 and cyclin B1 levels is rather speci®c, since neither cyclin D1 nor aactin were aected by PKR (Figure 8 ). There are several ways by which PKR could aect the cellular level of a given set of proteins. The most plausible way is inactivation of the translation initiation factor eIF2a and the subsequent general repression of the cell CHO:v-mos:PKR cells (clones 5 and 9) were seeded in 6 mm plates and were either untreated (control) or treated with muristerone A for up to 4 days. Viable cells were harvested and counted every 24 h. The cell numbers represent the mean values of ®ve independently repeated experiments that gave similar results translation machinery (Craddock et al., 1995; Squire et al., 1993) . How would PKR then preferentially aect those de®ned sets of cellular proteins? We could predict that the levels of short-lived proteins like cyclin B1 and proteins encoded by non-eciently translated mRNAs should preferentially be aected by PKR. To the last group belongs, among others, mRNAs encoding growth-controlling proteins. Some of these transcripts were shown to include several AUG initiation codons that precede the major translation initiation site and impair its functionality (Kozak, 1988) . Alternatively, the translation of some mRNAs could be preferentially repressed in PKR-overexpressing cells by virtue of their unique secondary structures. mRNAs containing unique stem and loop structures at their 3' untranslated sequences stimulated local activation of PKR and consequently local repression of their translation (Henry et al., 1994) . Thus, cyclin B1 and CDC2 seem to belong to the group of proteins whose cellular levels are preferentially aected by PKR. However one cannot exclude the possibility that PKR downregulates CDC2 and cyclin B1, at the transcriptional level, by aecting the level of a transcription factor that activates the transcription of the CDC2/cyclin B1 genes. Further characterization of proteins regulated by PKR should increase our understanding of the molecular mechanisms that underlie the cellular eects of that kinase. Down-regulation of CDC2 and cyclin B1 most probably leads to impairment of G2/M transition and to interference with cell proliferation. However, the eects of PKR on cell cycle regulators like CDC2 and cyclin B1 can be counteracted by oncogenes like v-mos, which by themselves, can aect the cellular levels and activity of these regulatory proteins. v-mos was shown to up-regulate E2F expression (Afshari et al., 1997) and consequently increases the mRNA and protein levels of CDC2 . It also prevents degradation of cyclin B1 by maintaining it in a highly phosphorylated form (Roy et al., 1990) . Thus, impairment of G2/M progression by PKR can be counteracted by an oncogene like v-mos that consequently abolishes the cytostatic activity of PKR. However, the counter eect of v-mos is rather speci®c and the oncogene did not abolish the activation of p53 and the induction of p21/WAF-1 by PKR ( Figure  11C,F) . This suggests also that p53 does not play a major role in the G2/M arrest imposed by PKR. Interestingly, the proapoptotic activity of PKR seems to be linked to the G2/M arrest imposed by the enzyme. This was best manifested by the fact that neither in G0/G1-arrested CHO cells, nor in deregulated growing cells (CHO : v-mos : PKR) could apoptotic activity of PKR be induced. These observations link the cytostatic and proapoptotic activities of overexpressed PKR to each other. A tight link between G2/M arrest and the onset of apoptotic processes has been shown in several triggers of apoptotic cascades (Chen and Ioannou, 1999; Ueda et al., 1999) . Moreover, peripheral blood leukocytes (PBL) from patients with chronic fatigue syndrome (CFS), exhibit signi®-cantly raised PKR levels (Vojdani et al., 1997) . Those cells contain increased apoptotic and S and G2/M arrested subpopulations. Interestingly, treating the PBL with the PKR inhibitor 2-aminopurine reduced the apoptotic cell population in some CFS patients and also those cell populations arrested in the S and G2/M phases. Thus, our results shed more light on the molecular mechanisms that may underlie the role of PKR in CFS. The link between PKR-mediated apoptosis and G2/M arrest may also explain the lack of apoptosis in PKR overexpressing and dierentiating myogenic cells that are arrested at the G0/G1 phase (Kronfeld-Kinar et al., 1999; Salzberg et al., 2000) .
Understanding the regulation and function of overexpressed PKR, may thus, elucidate its role in overexpressing tumor cells like mammary cell carcinoma (Kim et al., 2000) and in pathological situations like CFS.
Materials and methods
Plasmids
The pIND-PKR plasmid was constructed as follows: The murine PKR cDNA was isolated from a pcDNA 3.1 (zeocin)/ PKR plasmid (a kind gift from N Zonnenberg) that was cut with HindIII and BamHI. The cDNA¯anked with HindIII and BamHI was then inserted into a HindIII ± BamHI cut pIND plasmid .
Cells infection and transfection
CHO cells were grown in Dulbecco's modi®ed Eagle's medium (DMEM) supplemented with 10% fetal calf serum. CHO cells were transformed with the v-mos oncogene by infection with the murine moloney sarcoma virus 5 (MoMuSV). Mo-MuSV 5 is a clonal isolate from the original Mo-MuSV stock Cells (2610 5 ) were seeded 24 h before infection in 100 mm dishes containing DMEM with Poly- Figure 11 PKR does not down-regulate CDC2 and cyclin B1 in CHO : v-mos : PKR cells. Whole-cell protein extracts were prepared from CHO : v-mos:PKR cells (clones 5 and 9), either untreated (7) or treated (+) with muristerone A for up to 72 h. Proteins were reacted with (A) a CDC2; (B) a cyclin B1; (C) a p21/WAF-1, (E) a actin and (F) app53 antibodies, in a Western blot analysis. Experiments in B ± E were carried out with clone 5 cells. (D) PKR was partially puri®ed from whole cell extracts of CHO : vmos : PKR cells (clone 5) either untreated (7) or treated (+) with muristerone A for 72 h, and was then subjected to an in vivo kinase assay. The 32 P-labeled, autophosphorylated enzyme was resolved in a SDS ± PAGE and was then detected by autoradiography PKR down-regulates CDC2 and cyclin B1 Y Dagon et al brene (4 mg/ml). The cells were then infected by 1-h incubation with polybrene containing medium which was collected from M-MuSV producer cell line. Transformed clones were selected and the expression of v-mos in each clone was veri®ed using Northern blot analysis (data not shown). Stably transfected cell lines were derived from native and from v-mos-transformed CHO cells that were transfected with DNA/lipofectamine (Gene Therapy System, Inc.) mixtures in two consecutive stages. The parental cell line expressing the ecdysone receptor was obtained by transfecting CHO cells with the pVgRX expression plasmid . Transfected cells were selected in medium containing 25 mg/ml Zeocin . Accumulation of functional ecdysone receptor was con®rmed by a transient transfection assay in which the reporter plasmid pIND/lacZ was expressed in resistant clones. Clones accumulating muristerone A-dependent b-galactosidase activity (data not shown) were transfected with the pIND-PKR plasmid and then selected for ectopic and regulated expression of the murine PKR. Retransfected cells were selected in medium containing 400 mg/ml G418, and clones were isolated within 3 weeks of selection. Established clones were treated with muristerone A and were analysed for expression of an intact PKR protein by applying Western blot analysis with polyclonal aPKR antibodies. Cell lines expressing ectopic PKR in an ecdysone dependent manner were maintained in medium containing 25 mg/ml Zeocin and 400 mg/ml G418.
Immunoblot analysis
Cells were washed twice with a phosphate buered saline (PBS) and were then lysed in RIPA buer (0.1% SDS, 1% Nonidet P-40 (NP40), 50 mM Tris HC; pH 7.5, 150 mM NaCl, 2 mg/ml leupeptin and 2 mg/ml aprotinin). The lysates were cleared by 20 000 g centrifugation for 10 min at 48C. Thirty mg protein from each sample were denatured in Laemmli sample buer (6% SDS 30% glycerol, 0.02% bromophenol blue, 200 mM Tris-HC; (pH 6.8), and 250 mM b-mercaptoethanol), at 958C for 5 min. The samples were resolved in SDS-polyacrylamide gel electrophoresis (SDS ± PAGE), and fractionated proteins were blotted on to immobilon membrane. Non-speci®c binding in a Western blot analysis was prevented by immersing the membranes in blocking buer (5% nonfat dry milk in Tris-buer salineTween 20 (TBS-T)), for 2 h at room temperature. The membranes were then exposed to: a PKR, a CDC2, a cyclin B1, a cyclin D1, a actin, a p21/WAF-1, and app553 (directed against p53 phosphorylated on Ser 392 ), commercial antibodies (Santa-Cruz), for 1 h at room temperature. The blots were rinsed in TBS-T and were then incubated with horseradish peroxidase-conjugated goat anti-mouse antibodies for 1 h at room temperature. Antibody-antigen complexes were visualized by detecting enhanced chemiluminescence with X-ray ®lm, according to the manufacturer's instructions.
Determination of PKR in vitro kinase activity
Cell extracts were prepared as described above. Heparin (50 ± 100 units/ml) was added to samples containing 500 mg protein each. The mixtures were incubated for 10 min at 48C. An equal volume of poly(I . C)-Sepharose beads was then added at room temperature with occasional gentle mixing for 30 min. The poly(I . C)-Sepharose beads were washed three times with buer B (50 mM KCL, 2 mM Mg-acetate, 7 mM bmercaptoethanol, 20% glycerol, and 10 mM HEPES pH 7.6) and then once with buer C (buer B supplemented with 1 mCi [g-32 P]ATP) and were then incubated for 30 min at 308C. After centrifugation, the pellet was washed three times with buer C and was then resuspended in two-thirds volume buer C and one-third volume electrophoresis sample buer. Supernatants were collected and analysed in 10% SDS ± PAGE. The gel was dried and the phosphorylated proteins were detected by autoradiography.
Analysis of cell-growth
To determine the rate of cell growth, 2610 4 cells were seeded in a 60 mm plate with or without muristerone A. The medium was replaced every 72 h and two plates were rinsed twice with PBS at the indicated time points to remove dead cells and debris. Cells were trypsinized, collected separately from each plate and live cells excluding trypan blue were then counted at least three times. The average numbers of cells from ®ve independent experiments were used for the determination of growth rate.
Cell cycle analysis and annexin V staining assay
Cells were seeded at 2610 5 per 60 mm plate with or without muristerone A. For DNA histogram analysis, both¯oating dead cells in the medium and live cells on the plate, were collected and ®xed with 1 ml 70% ethanol. The ®xed cells were centrifuged and resuspended in 1 ml PBS solution containing 50 mg/ml of each RNase A and propidium iodide. Stained cells were analysed for relative DNA content by a Coulter FACSort (Becton Dickinson)¯ow cytometer. The percentage of cells residing in the sub-G1, G0/G1, S, and G2/ M fractions were determined using the multicycle program. For annexin V staining assay. Cells were treated with 100 mg/ml poly(I . C), 18 h before being harvested. In a selected experiment, 5 mM 2-aminopurine was added to the cells, concomitantly with the Poly(I . C) treatment. Both dead and live cells were collected and washed with cold PBS. The cells were then resuspended in 0.2 ml annexin V binding buer (Bender med. Systems inc.) and were brought to a density of 2 ± 5610 5 /ml. Cells were then stained with annexin V according to the manufacturer's instructions. Binding of annexin V was determined in the Coulter FACSort.
